3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
6
CNS
3
Endocrine
2
Plasma cell
1
NET
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
13
Sarcoma
5
Testicular Neoplasms
4
Astrocytoma
4
Wilms Tumor
3
Optic Nerve Glioma
3
Oligodendroglioma
3
Neuroectodermal Tumors, Primitive, Peripheral
3
Neuroblastoma
3
Medulloblastoma
3
Kidney Neoplasms
3
Familial ependymoma
3
Fallopian Tube Neoplasms
3
Choroid Plexus Neoplasms
3
Central Nervous System Neoplasms
3
Triple Negative Breast Neoplasms
2
Testicular Germ Cell Tumor
2
Teratoma
2
Ovarian Germ Cell Cancer
2
Osteosarcoma
2
Liver Neoplasms
2
Head and Neck Neoplasms
2
Glioma
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Endometrial Stromal
1
Sarcoma, Alveolar Soft Part
1
Interventions
pembrolizumab
27
Cyclophosphamide
14
Gemcitabine
13
fludarabine
11
Carboplatin
10
aldesleukin
9
Trastuzumab
9
Specimen Handling
9
Nivolumab
9
Magnetic Resonance Spectroscopy
8
Biopsy
8
olaparib
7
Cisplatin
7
Paclitaxel
6
palbociclib
5
atezolizumab
5
Taxes
5
Early Intervention, Educational
5
Oxaliplatin
4
Methods
4
Irinotecan
4
Drug Therapy
4
Docetaxel
4
Cetuximab
4
Capecitabine
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
talazoparib
3
spartalizumab
3
pertuzumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Temozolomide
×
Gynecologic
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled